Aug 25, 2008
ASCO: Bevacizumab (Avastin) Alone Shows Edge in Recurrent Glioblastoma 

PHILADELPHIA, Aug. 25 -- Most hereditary neuroblastomas in children, as well as many sporadic cases, are attributable to mutations in a known cancer-associated gene, researchers here said.   <READ MORE>

May 30, 2008
ASCO: Bevacizumab (Avastin) Alone Shows Edge in Recurrent Glioblastoma 

CHICAGO, May 30 -- For refractory glioblastoma, second-line bevacizumab (Avastin) as monotherapy has been associated with a 28% response rate and an overall survival edge, albeit nonsignificant, over the agent plus irinotecan (Camptosar).  <READ MORE>

Jan 18, 2008
Implant Combination Prolongs Survival in Glioblastoma 

CINCINNATI, Jan. 18 -- Survival in recurrent glioblastoma multiforme was extended without major toxicity by low-activity iodine-125 seeds and carmustine wafers (Gliadel) implanted simultaneously during brain surgery, researchers here said.  <READ MORE>

Jan 2, 2008
Negative Brain Mapping May Be a Positive for Glioma Surgery

SAN FRANCISCO, Jan. 2 -- When attempting to preserve language function during glioma resection, brain mapping that isolates areas without speech involvement may be more efficient than seeking areas with them.  <READ MORE>

Oct 30, 2007
ASTRO: Temozolomide (Temodar) Offers Long-Term Survival for Glioblastoma

LOS ANGELES, Oct. 30 -- More glioblastoma patients are living longer when the oral alkylating agent temozolomide (Temodar) is combined with radiation therapy, found Swiss researchers.  <READ MORE>